pSivida Corp., formerly pSivida Limited. develops drug delivery products that are administered by implantation, injection or insertion. Once administered, the drug is released on a controlled and level basis for months or years. The Company has developed with partners two of the only three products approved by the United States Food and Drug Administration (FDA) for the long-term, sustained release delivery of drug to treat chronic eye disease, and a third partnered product is in late-stage Phase III clinical trials. Its Phase III partnered product, which utilizes the third-generation of its Durasert technology system, delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME). The Company has three technology systems: Durasert, BioSilicon and CODRUG. The Company’s lead BioSilicon product candidate, BrachySil, delivers therapeutic phosphorus-32, or P32, a radioactive form of phosphorus used to treat cancer, directly to solid tumors.